Provectus Tries To Put A Positive Spin On PV-10 “Breakthrough” Denial
Executive Summary
FDA letter rejecting “breakthrough therapy” status for investigational melanoma treatment is released by the company in an apparent bid to rally support for the drug. The strategy had the opposite effect, however, causing Provectus’ stock to plummet and demonstrating the perils of breakthrough-related disclosures.